

Cite this: *J. Mater. Chem.*, 2012, **22**, 7214

www.rsc.org/materials

PAPER

Quantifying apatite formation and cation leaching from mesoporous bioactive glasses *in vitro*: a SEM, solid-state NMR and powder XRD study†Philips N. Gunawidjaja,^a Isabel Izquierdo-Barba,^{bc} Renny Mathew,^a Kjell Jansson,^d Ana García,^{bc} Jekabs Grins,^d Daniel Arcos,^{bc} María Vallet-Regí^{bc} and Mattias Edén^{*a}

Received 7th October 2011, Accepted 23rd January 2012

DOI: 10.1039/c2jm15066b

By employing solid-state nuclear magnetic resonance (NMR) spectroscopy, powder X-ray diffraction (PXRD), and scanning electron microscopy coupled with energy-dispersive X-ray (EDX) spectroscopy, we compare the biomimetic growth of calcium hydroxyapatite (HA) from an ordered mesoporous bioactive glass (MBG) in simulated body fluid (SBF) and buffered water solutions. For the latter medium, we also examine the effects of using two different MBG concentrations. We evaluate the predicting powers of PXRD and ³¹P NMR for directly quantifying the relative amounts of biomimetic amorphous calcium phosphate (ACP) and HA: we observe a very good agreement between the two analytical techniques. Thanks to their mesoporous channel system, fluids readily penetrate throughout sub-mm sized MBG grains, as evidenced by EDX. The latter revealed distinct element-mappings across the material after its exposure to SBF compared to water. Under our *in vitro* conditions involving relatively high MBG-loadings in the solutions, the HA formation reduces in SBF relative to buffered water, particularly for increasing MBG concentration. These features stem from a high [Ca²⁺]/[PO₄³⁻] ratio resulting in the fluid medium, which retards the HA crystallization by inducing a rapid ACP precipitation and an accompanying depletion of phosphate ions in the solution. This has bearings on the design of bioactivity comparisons of bioglasses exhibiting significantly different cation compositions.

1. Introduction

Thanks to their bone-bonding properties originating from a growing hydroxy-carbonate apatite (HCA) surface layer when subjected to body fluids, silicate-based *bioactive glasses* (BGs) have found several clinical and technological applications, such as in dentistry, as bone-filling materials and additives in toothpaste.^{1–5} The preparation routes of BGs have undergone significant developments, currently encompassing melt-quench, sol–gel, as well as evaporation-induced self-assembly (EISA)⁶ techniques: particularly the latter has been exploited recently for producing *mesoporous bioactive glasses* (MBGs).^{7–11} They feature

an enhanced bioactivity mainly due to their *ordered* arrangement of mesopores and very large surface area,^{7–11} as well as a unique nano-structured pore-wall constitution.^{12–14}

Comparative *in vitro* “*bioactivity*” evaluations of (M)BGs displaying different compositions, textures or synthesis routes are traditionally assessed by the relative amounts of HCA formed at their surfaces per unit exposure-period in a simulated body fluid (SBF):^{1–3,15} the faster the *in vitro* HCA formation, the higher the bioactivity. However, such evaluations reported in the literature often differ substantially in their testing conditions. Disregarding controversial issues such as whether HCA-formation in SBF is a faithful indicator of the *in vivo* bone-bonding properties of BGs,^{16–18} a large number of both *external* and *internal* (i.e., inherent to the material) factors may affect the apparent *in vitro* bioactivity. External conditions encompass, for instance, the pH and temperature of the solution,^{18,19} if tests employ a “stationary” or “flowing” medium,^{20,21} or whether the specimen is in the form of a bulk piece/pellet, sub-mm sized grains or a fine powder. Furthermore, the BG concentration and the ratio between the surface area of the material and the volume of the solution may have profound bearings on the bioactivity assessment.^{22–25}

In the quest for finding the “ideal” BG, it is normally its bioactivity-dependence on the internal material properties—such

^aPhysical Chemistry Division, Department of Materials and Environmental Chemistry, Arrhenius Laboratory, Stockholm University, SE-106 91 Stockholm, Sweden. E-mail: mattias.eden@mmk.su.se; Fax: +46 8 152187; Tel: +46 8 162375

^bDepartamento de Química Inorgánica y Bioinorgánica, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain

^cNetworking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain

^dInorganic and Structural Chemistry Division, Department of Materials and Environmental Chemistry, Arrhenius Laboratory, Stockholm University, SE-106 91 Stockholm, Sweden

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c2jm15066b

as its composition, structure, and texture—that constitute the desirable targets for evaluation. While the development and assessments of BGs have traditionally featured a high degree of empirical testing, several comprehensive studies are reported that unveil bioactivity/composition relations and to a lesser extent their link to the glass structure.^{26–32} Despite that elucidating the relationship between the internal material properties and the HCA formation is ideally targeted, the external conditions are often difficult to control precisely so as to provide unbiased comparisons of different bioglasses (or biomaterials *vide infra*).

Another complication for bioactivity evaluations is the potentially (very) different results emerging from the particular experimental technique employed for probing the HCA formation, which should *ideally* translate into a direct quantification of the “bioactivity” and its relationship to the internal (M)BG properties. Current investigations have predominantly utilized either powder X-ray diffraction (PXRD), infrared spectroscopy, or scanning and transmission electron microscopy (SEM/TEM),^{7–11,19–25} and less frequently solid-state nuclear magnetic resonance (NMR) spectroscopy.^{13,33–36} Yet, reports to date are qualitative rather than quantitative.

Herein, we consider the apatite growth at the surface of an “S85”^{9,10} ($10\text{CaO}-85\text{SiO}_2-5\text{P}_2\text{O}_5$) MBG in SBF as well as in water buffered by tris(hydroxymethyl)-aminomethane (TRIS). We also investigate the consequences of employing two different S85 concentrations in the latter medium (labelled “TRIS” hereafter). Our S85-deriving specimens are henceforth referred to as “ $sbft_{\tau m}$ ” or “ $trist_{\tau m}$ ”, where τ denotes the soaking interval (8 h or 16 h) and m the mass of MBG per litre of SBF or TRIS solution, respectively. This work serves a three-fold purpose:

(i) The biomimetic calcium phosphate layer generated *in vitro* at the (M)BG surface over short time periods comprises a mixture of amorphous calcium phosphate (ACP) and structurally ordered HCA. We recently exploited solid-state ^{31}P NMR to quantify the relative amounts of amorphous and crystalline phosphates,¹³ while PXRD has been applied routinely to qualitatively probe the *in vitro* apatite-formation of (M)BGs; *e.g.*, see ref. 2,13,14,20,23,25,33–35,37 and 38. *In situ* XRD studies are also reported.³⁹ However, PXRD has to our knowledge not yet been utilized to *directly* assess the ACP and HCA contents of the biomimetic surface layer. In Sections 2.1 and 2.2, we evaluate the relative merits of PXRD and solid-state ^{31}P NMR for making such quantifications.

(ii) We explore the release of Ca, P and Si from the MBG, as probed either *globally* from analyzed cation concentrations in the solution following S85-soaking (Section 2.3) or over a $\sim 200\ \mu\text{m}$ range *within* the leached S85 structure itself through an element-mapping by SEM coupled with energy-dispersive X-ray (EDX) spectroscopy (Section 2.4). SEM/EDX evidences a deep penetration of the surrounding fluid into the MBG structure, hence underlining/evidencing its highly efficient release of Ca and P observed herein, as well as in previous reports.^{7–10}

(iii) In Sections 2.5 and 2.6, we compare and discuss the results of (i) and (ii) by illustrating how the particular design of the *in vitro* study may affect the HCA formation, and hence the apparent *in vitro* “bioactivity”. This concerns the medium employed for MBG soaking (SBF or TRIS solution) as well as the stoichiometric composition and concentration of the MBG. Under conditions of high S85-loadings, higher HCA formation is

observed from the TRIS medium compared to SBF. Further, the failure of producing HCA from a previously evidenced *bioactive* “S58”^{9,10} ($37\text{CaO}-58\text{SiO}_2-5\text{P}_2\text{O}_5$) MBG specimen will be rationalized as stemming from interferences of our particular *in vitro* conditions with the Ca-rich nature of this MBG.

2. Results and discussion

2.1 ^{31}P NMR results

Fig. 1 displays ^{31}P magic-angle spinning (MAS) NMR spectra recorded by single pulses from pristine S85 and the $sbft_{20}$ and $trist_m$ specimens. Both the S85 MBG and a crystalline hydroxyapatite reference specimen (“HAref”) produce ^{31}P NMR peak maxima around 3 ppm, as expected from their common calcium orthophosphate structural building blocks.^{12,40} However, the NMR response from the well-ordered HAref structure features a narrow Lorentzian peak, whereas that from the MBG is significantly broader and Gaussian-shaped: the latter NMR features are typical of structurally disordered phosphates.⁴⁰ The Ca^{2+} and PO_4^{3-} ions within/at the $\text{CaO}-\text{SiO}_2-\text{P}_2\text{O}_5$ MBG pore-wall form nm-sized disordered clusters,^{12–14} henceforth referred to as “CaP”. They share several NMR characteristics with the ACP layer initially forming at the MBG surface on its contact




Fig. 1 ^{31}P MAS NMR spectra acquired by single pulses from samples of (a) pristine S85 (black trace) and crystalline HAref (grey line), and after soaking S85 in TRIS or SBF solutions for (b) 8 h and (c) 16 h. The distinct colors identify each NMR spectrum by its respective $sbft_{\tau m}$ and $trist_m$ specimen, with m given by $3\ \text{g L}^{-1}$ or $20\ \text{g L}^{-1}$. Numbers at the right specify the respective fwhm (in ppm) of the main orthophosphate ^{31}P NMR peak. The grey rectangle in (a) marks a minor resonance assigned to P–O–Si moieties.^{12,13}

with (simulated) body fluids, which underlines their similar local structural features.^{12,13,41}

The ³¹P NMR signals stemming from the SBF/TRIS-exposed S85 specimens are shown in Fig. 1(b and c). The NMR peak in each spectrum is a superposition of one narrow and one broad component, signifying the co-existence of an ordered (*i.e.*, apatite) and one or several disordered (*i.e.*, CaP and ACP) phases, respectively.^{13,41} In buffered water, ACP converts into HA, whereas the presence of additional ions in the SBF, notably CO₃²⁻, leads to formation of HCA, as in biomineralized tissues.^{1–3} Henceforth, we use the label “H(C)A” when referring collectively to the biomimetic apatite produced either in SBF or TRIS solutions. While the NMR peak maximum remains at 3 ppm throughout, and all spectra in Fig. 1(b and c) manifest a noticeable peak-narrowing as the SBF or TRIS immersion period increases, the TRIS-soaked samples display consistently lower full-width at half maximum (fwhm) height values of their ³¹P NMR peaks. This signal-narrowing is even more pronounced for the tris16h₃ sample compared to its tris16h₂₀ counterpart. As the NMR peak-width reflects the structural order of the orthophosphate environments, the results in Fig. 1(b and c) evidence an accelerated ACP → HA conversion as the amount of MBG per solution volume decreases.

Table 1 lists the results from deconvoluting the peak of each ³¹P NMR spectrum into signals from the ACP and H(C)A components; see Fig. S1 of the ESI†. Further discussion and a justification for this procedure are provided by Gunawidjaja *et al.*¹³ The results reveal quantitatively the enhanced H(C)A formation as either (i) the MBG-soaking interval increases, (ii) a TRIS solution is employed instead of SBF and (iii) the concentration of the MBG (m_{S85}/V) decreases from 20 g L⁻¹ to 3 g L⁻¹. The impact on the ACP → H(C)A conversion from each of these factors—where (ii) and (iii) are remarkably strong—is examined and rationalized in the remainder of this paper. We stress that the same pristine S85 MBG was employed throughout all *in vitro* studies, which highlights the profound influences from external factors on the “apparent bioactivity”. The three distinct specimens resulting after 16 h of SBF/TRIS immersion display variations between 0.43 and 0.61 in their estimated fractions of H(C)A (Table 1): this amounts to >30% relative difference in the bioactivity assessment of the same biomaterial.

2.2 Quantification of H(C)A: PXRD versus NMR

The PXRD patterns shown in Fig. 2 verify that the pristine S85 MBG exhibits the characteristics of an amorphous sample, whereas all diffraction peaks revealed from the sbfτ₂₀ and trisτ_m specimens may be assigned to apatite. These results corroborate the trends inferred by ³¹P NMR: besides unambiguously evidencing the presence of H(C)A even at the shortest soaking interval of 8 h, PXRD confirms that when the MBG concentration remains constant at the high level of 20 g L⁻¹, the apatite formation enhances in the TRIS medium relative to SBF. Further, it is significantly boosted either for increasing exposure period or as the m_{S85}/V ratio decreases.

The PXRD patterns were used to estimate the relative fraction of H(C)A out of the total phosphorus content of each sample, by using the Rietveld method and the FullProf program.⁴² A similar approach has been employed to derive the HCA fraction out of all crystalline phases (*e.g.*, HCA, calcite and quartz) potentially




Fig. 2 Powder X-ray diffractograms obtained from HArefer (bottom) and the as-indicated SBF or TRIS exposed S85 samples.

Table 1 ³¹P NMR and PXRD data^a

Sample	Net NMR peak		ACP [NMR]		Fraction	H(C)A [NMR]			H(C)A [PXRD] ^b
	δ _{max} (ppm)	fwhm (ppm)	δ (ppm)	fwhm (ppm)		δ (ppm)	fwhm (ppm)	Fraction	
S85	3.06	6.30 ± 0.08	2.83	6.22	1.00				
sbf8h ₂₀	3.24	3.46 ± 0.05	3.40	5.58	0.66	3.24	2.13	0.34	0.26
sbf16h ₂₀	3.22	2.81 ± 0.04	3.56	5.36	0.57	3.18	1.94	0.43	0.39
tris8h ₂₀	3.04	2.78 ± 0.04	3.26	5.34	0.60	3.12	1.85	0.40	0.19
tris16h ₂₀	3.06	2.50 ± 0.04	3.36	5.33	0.50	3.08	1.80	0.50	0.48
tris16h ₃	3.06	1.91 ± 0.03	3.15	4.58	0.39	3.11	1.60	0.61	0.65
HArefer	3.06	0.67 ± 0.02							

^a Results of deconvoluting each NMR peak in the spectra of Fig. 1 into contributions from amorphous (CaP/ACP) and ordered (H(C)A) phosphate components. The second and third columns list the peak maxima (δ_{max}) and full-width at half maximum (fwhm) of the net ³¹P NMR peak; the uncertainty (±0.05 ppm) of δ_{max} is primarily dictated by the external chemical shift referencing. Best-fit parameter-uncertainties: for ACP (δ ± 0.15 ppm; fwhm ± 0.2 ppm); for H(C)A (δ ± 0.08 ppm; fwhm ± 0.1 ppm); relative fractions ±0.025. ^b PXRD-determined fraction of H(C)A out of the total P content.

forming on SBF-exposure of BGs.³⁸ However, PXRD has to our knowledge hitherto not been utilized to determine the relative ACP and H(C)A contents of the biomimetic calcium phosphate layer.

Our procedure assumes that the *in vitro*-formed H(C)A exhibits the nominal HA stoichiometry, $[\text{Ca}_5(\text{PO}_4)_3(\text{OH})]$. Initial quantifications were obtained by dividing refined scale factors obtained from the MBG specimens by that of the HA_{ref} sample. However, several factors thwart a direct proportionality between the summed diffraction intensity of the H(C)A phase and its fraction, including variations of the X-ray absorption of the sample with the apatite content, insufficient thickness of the sample, as well as micro-absorption effects.⁴³ The first factor is usually dominating, but it may readily be accounted for in the present two-phase mixture, provided that the distinct absorption characteristics of the H(C)A and amorphous SiO₂-dominated MBG constituents are known. These X-ray mass absorption coefficients were employed to calculate a corrected weight fraction of H(C)A (denoted c_A^{corr}), according to the procedure of ref. 43,

$$c_A^{\text{corr}} = \frac{c_A(\mu/\rho)_S}{(\mu/\rho)_A - c_A[(\mu/\rho)_A - (\mu/\rho)_S]}, \quad (1)$$

where $(\mu/\rho)_A = 86.4 \text{ cm}^2 \text{ g}^{-1}$ and $(\mu/\rho)_S = 35.9 \text{ cm}^2 \text{ g}^{-1}$ are the respective mass absorption coefficients for apatite (A) and SiO₂ (S) and c_A denotes the uncorrected weight fraction of H(C)A. From the estimated H(C)A content in each specimen, its relative amount out of all P-bearing phases was calculated, by assuming the total XRF-analyzed P content of the pristine S85 MBG (2.9 wt%) for all specimens. This assumption is well justified under our *in vitro* conditions: the levels of Ca²⁺ and PO₄³⁻ ions remaining in the solutions are low (see Section 2.3); furthermore, the entire P population derives from S85 in the case of the *tristm* samples, whereas the high loading in SBF ($m_{\text{S85}}/V = 20 \text{ g L}^{-1}$) implies that the MBG constitutes the predominant P-source (~95%) also for the *sbftm* specimens. Under more dilute SBF-soaking conditions, where the relative phosphate uptake from the solution may be significant, an independent estimate of the total P content is necessary for each MBG-deriving specimen.

Despite that the H(C)A contents determined by PXRD are typically slightly lower than their NMR-derived counterparts (see Table 1), an excellent correlation is observed for four out of five estimations, as evidenced by Fig. 3. Each analytical technique is associated with its pros and cons: notwithstanding the relatively high receptivity of the ³¹P nucleus, MAS NMR experimentation is more time-consuming than that of PXRD for routine sample screening. However, NMR offers a decisive advantage in its straightforward extraction of the H(C)A content, only requiring signal-deconvolution into two components, while its element-specific feature makes the assessment-accuracy independent of the fraction of phosphate-bearing phases present in the specimen. Yet, when the molar ratio of H(C)A relative to ACP is small (<0.2), the ³¹P NMR signal-deconvolution becomes inherently inaccurate, then making quantifications by PXRD preferred.

The main deficiency of our PXRD quantification procedure constitutes the assumption that the biomimetic H(C)A exhibits the HA stoichiometry. We have verified that its violation implies a relative error in the estimated fraction being roughly equal




Fig. 3 The correlation between the relative H(C)A fractions out of the total calcium phosphate content, as estimated by PXRD using eqn (1) (vertical axis) and by ³¹P NMR (horizontal) for the indicated samples. The straight line corresponds to the best-fit result (correlation coefficient $R^2 = 0.998$) when excluding the result from the *tris8h*₂₀ specimen.

to the discrepancy between the stoichiometric $n_{\text{Ca}}/n_{\text{P}}$ ratio of the actual H(C)A phase and the as-assumed HA-value of $n_{\text{Ca}}/n_{\text{P}} = 5/3$. Whereas the $n_{\text{Ca}}/n_{\text{P}}$ ratio may be determined by electron microscopy, the significantly increased efforts towards resolving this issue make ³¹P MAS NMR an attractive alternative for determining the relative H(C)A content.

In conclusion, we favour ³¹P MAS NMR as the method of choice for self-consistently estimating relative H(C)A contents, provided that a sufficiently large amount of the sample is available (>100 mg).

2.3 MBG dissolution in TRIS-buffered water

To assess the extent of degradation of the S85 MBG for the relatively short immersion periods of 8 h and 16 h employed herein, the concentrations of calcium-, silicon- and phosphorus-bearing ions were measured in the solution remaining after removal of each *tristm* specimen (see Table 2). Fig. 4(a) plots the results together with the pH value of each solution, including that of the initial TRIS medium (pH = 7.45).

Whereas the pH value only increases marginally (by up to 0.15) over the 16 h of soaking, and the Si concentration remains essentially constant at $\sim 2.56 \text{ mmol L}^{-1}$ ($\sim 72 \text{ mg L}^{-1}$)—indicating its saturation throughout all tests—the relative concentrations of Ca and P vary substantially. Due to the ACP/HA precipitation, they are overall higher in the solutions associated with shorter exposure periods, $\tau = 8 \text{ h}$, relative to those at 16 h. While the $[\text{Ca}^{2+}]$ is elevated throughout in the solutions comprising the higher amount of S85 (*i.e.*, *trist*₂₀), it does not change significantly for increasing soaking interval within each pair of {*tris8h*₂₀, *tris16h*₂₀} and {*tris8h*₃, *tris16h*₃} samples. However, $[\text{PO}_4^{3-}]$ drops markedly when τ lengthens, signifying a very rapid initial ion release from S85, followed by a phosphorus consumption due to the subsequently dominating ACP/HA formation processes. Compare the Ca²⁺ and PO₄³⁻ concentrations of the solutions belonging to the *tris8h*₂₀ and *tris16h*₂₀ specimens: the decrease in $[\text{Ca}^{2+}]$ matches well 1.66 times that of the accompanying decrease in $[\text{PO}_4^{3-}]$, *i.e.*, as expected for

Table 2 Dissolution data for S85-soaking in TRIS solution^a

Sample	pH	[Si]/mmol L ⁻¹	[Ca]/mmol L ⁻¹	[P]/mmol L ⁻¹	x_{Si}	x_{Ca}	x_{P}	[Ca]/[P]
<i>tris</i> 8h ₂₀	7.56	2.55	2.91	0.27	0.010	0.101	0.014	11
<i>tris</i> 16h ₂₀	7.59	2.55	2.56	0.06	0.010	0.089	0.003	45
<i>tris</i> 8h ₃	7.51	2.65	1.00	0.20	0.070	0.231	0.073	4.9
<i>tris</i> 16h ₃	7.51	2.56	1.16	0.36	0.068	0.268	0.128	3.3

^a Analyzed pH-value (uncertainty ± 0.03) and molar concentrations (all within $\pm 2.5\%$) of each solution remaining after removal of the respective *tris* τ_m solid phase. Each fraction x_E ($E = \text{Si}, \text{Ca}, \text{P}$) is calculated from the net amount of element E present in the solution, divided by its respective initial amount of the pristine S85 sample.




Fig. 4 (a) Variations of the Si, Ca and P concentrations (left axis) and pH-values (right axis) in the solutions corresponding to the as-indicated TRIS-soaked S85 samples. The dotted horizontal line marks the initial pH-value of the TRIS solution. (b) Degree of dissolution, *i.e.*, the fraction of each element present in the solution relative to the total amount initially present in the pristine S85 MBG.

precipitation of a calcium phosphate of approximate HA composition. Such a directly interrelated reduction in the Ca^{2+} and PO_4^{3-} concentrations is not observed from the two *tris* τ_3 counterpart solutions, presumably as it is obscured by the non-negligible MBG dissolution that becomes emphasized under these more dilute conditions.

Fig. 4(b) displays the fraction of each element dissolved from S85 for each soaking-interval and MBG content per unit solution volume. This representation conveys more transparently the degree of ion-release from the MBG pore-walls when using S85 concentrations of either 3 g L^{-1} or 20 g L^{-1} (that relate by a factor of 6.67). The nearly constant [Si] in the TRIS solutions translates for the MBG mass/volume ratio of 20 g L^{-1} into a negligible Si release of $\sim 1\%$ of the entire reservoir, whereas the dissolution is ~ 6.7 times higher under the more dilute conditions of 3 g L^{-1} , *i.e.*, the *tris* τ_3 specimens. They also display the largest dissolution degree for Ca and P, amounting roughly to 25% and 10%, respectively. The real extents of Ca and P release from the S85 sample during each immersion period are substantially larger than hinted from Fig. 4(b), as it merely reveals the net amounts of ions remaining in the solution after precipitation of ACP and its

subsequent crystallization into HA. The latter process dominates at the longer exposure interval of 16 h.

2.4 SEM/EDX results

SEM/EDX was utilized to investigate the microstructure and composition gradients within the SBF/TRIS-leached S85 material. Fig. 5(a) shows a micrograph recorded from pristine S85. An EDX analysis of 50 spots from distinct grains provided the composition $\text{Ca}_{0.11}\text{Si}_{0.81}\text{P}_{0.08}\text{O}_{1.93}$, which accords well with the result from X-ray fluorescence (XRF) spectroscopy (see Section 3.1). The micrograph of Fig. 5(b) was obtained from the *shf*16h₂₀ specimen: it reveals a thin surface layer comprising numerous small HCA crystallites. Note that the lower right portion of the image resulted by scratching off the phosphate layer to reveal the




Fig. 5 (a–d) SEM micrographs recorded from grains of the (a) pristine and (b–d) *shf*16h₂₀ specimens. (b) An image revealing the ACP/HCA-coated MBG surface. (c) A collection of small particles close to a large one. (d) Zoom around the cross-section of one small grain [marked by the dashed box in (c)]. Note the slightly varying thickness (1–2 μm) of the ACP/HCA surface layer (light grey). (e–g) EDX spectra recorded from (e) pristine S85 and at the as-indicated spots in the image of (d). The analyzed amounts of Si, Ca and P in at% (out of the cations) are specified in (c) and (e–g).

underlying MBG surface. The variable MBG particle sizes are illustrated for the *sbfl6h₂₀* specimen in Fig. 5(c), whose image depicts a collection of smaller particles clustered around the surface of a large grain. Fig. 5(d) shows the cross-section of one such small particle.

Thanks to the bicontinuous cubic mesoporous channel system of S85,^{9,10} surrounding fluids may readily access the centre of even sub-mm sized particles. The cation leaching discussed in Section 2.3 is mirrored in the EDX results at selected spots within the grain displayed in Fig. 5(c): they exhibit substantially lower amounts of Ca and P after 16 h of SBF treatment, which reflects the well known “silica-gel layer” discussed in the contexts of sol-gel- and melt-prepared BGs subjected to SBF.^{1,2,33,37,44–46} Generally, small MBG particles (<15 μm) manifest a total depletion of Ca and P across the material (Fig. 5(d and f)), whereas EDX spectra recorded at their surface evidence pure calcium phosphate, as shown for *sbfl6h₂₀* in Fig. 5(g).

To probe the penetration depth of the fluid into the MBG and its bearings on the leaching of Ca^{2+} and PO_4^{3-} ions, systematic EDX spot-analyses were performed on selected (large) grains of the *tris16h₂₀* and *sbfl6h₂₀* specimens. Fig. 6 displays representative maps of their composition-gradients from the surface towards the particle interior. The XRF-analyzed content of each cation in S85 is indicated by the horizontal line in Fig. 6(a–c). Just beyond the 1–2 μm thick phosphate surface-layer, the *tris16h₂₀* grains reveal a domain ($\leq 60 \mu\text{m}$) of essentially pure silica, whereas those of *sbfl6h₂₀* exhibit small but significant amounts of both Ca and P throughout the leached layer. The analyzed compositions gradually change towards that of the initial S85 composition, which for *sbfl6h₂₀* and *tris16h₂₀* occur at about distances of 80 μm and 160 μm from the surface, respectively. The observed ion-concentration differences inside the leached S85 material in SBF and TRIS solutions are attributed to a more pronounced local precipitation of ACP occurring at the S85 pore-walls in the former medium (which is already supersaturated with respect to apatite), whereas the TRIS solution may dissolve larger fractions of Ca^{2+} and PO_4^{3-} ions until ACP formation initiates.

The corresponding analyzed sodium contents of *sbfl6h₂₀* and *tris16h₂₀* are plotted in Fig. 6(d). Sodium is well-known to substitute into the HCA structure formed *in vivo* and is also incorporated into biomimetic phosphate layers grown at MBGs in SBF.¹³ Note that Na is present solely in the SBF medium,¹⁵ and traces thereof are indeed exclusively revealed from particles of *sbfl6h₂₀* (as opposed to *tris6h₂₀*) throughout the entire analyzed distance. This establishes a very deep penetration of the solution into the MBG material.

2.5 Dependence of ion release and H(C)A formation on MBG concentration

The S85 MBG constitutes the entire source of Ca and P in the biomimetic ACP/HA phases formed in the TRIS solution. As demonstrated by both PXRD (Fig. 2) and ^{31}P NMR (Fig. 1 and Table 1), both the relative amount of HA and its crystallinity are higher in the *tris τ_3* samples obtained under more dilute soaking conditions compared to their *tris τ_{20}* counterparts. Hence, our results corroborate previous reports on melt-quench and sol-gel prepared BGs for variable amounts of bioglasses relative to the




Fig. 6 EDX spot analysis from large grains of the *sbfl6h₂₀* (black squares) and *tris16h₂₀* (grey circles) specimens: the analyzed at% of each specified element is plotted against the distance from the particle surface. The corresponding value obtained by XRF is indicated by the horizontal line, with the estimated uncertainty (± 1.5 percentage units) shown by the grey box. Note that (a–c) are plotted using the same vertical range of 20 percentage units (although the starting and ending values vary), whereas (d) employs an expanded scale.

SBF volume,^{22,23} where diminished HCA formation was observed as the BG concentration in the solution increased above a critical value. The inhibited $\text{ACP} \rightarrow \text{HA}$ crystallization stems from a rapid and substantial precipitation of ACP, leaving very low P contents of the remaining solutions accompanying the *tris8h₂₀* and *tris16h₂₀* solid phases.

The solutions associated with the *tris τ_3* samples display ratios of $[\text{Ca}^{2+}]/[\text{PO}_4^{3-}] \sim 3\text{--}5$ that remain closer to the value of ~ 1.7 (i.e., the molar ratio $n_{\text{Ca}}/n_{\text{P}}$ in HA), as compared to the markedly higher values $[\text{Ca}^{2+}]/[\text{PO}_4^{3-}] > 10$ in those employing $m_{\text{S85}}/V = 20 \text{ g L}^{-1}$ (see Table 2). We suggest that the H(C)A crystallization is facilitated when the $[\text{Ca}^{2+}]/[\text{PO}_4^{3-}]$ ratio in the solution approximately matches the $\text{Ca}_3(\text{PO}_4)_2$ stoichiometry (selected for simplicity, as its composition approximates well all other relevant phosphate phases that may form), whereas a ratio significantly higher than ~ 1.5 retards the $\text{ACP} \rightarrow \text{HA}$ conversion. This

may also explain the (counter-intuitive) observation of a reduced H(C)A growth observed from the SBF medium relative to TRIS under otherwise identical soaking conditions (Table 1 and Fig. 1 and 2). While the latter solution is devoid of both Ca^{2+} and PO_4^{3-} ions, they are present in SBF. Yan *et al.* suggested that the $\text{ACP} \rightarrow \text{H(C)A}$ crystallization process stops when insufficient amounts of PO_4^{3-} ions are available to ensure a critical thickness of the ACP layer to allow for crystallization.²² In the present case, this may be interpreted as follows: the fluid present inside the MBG pore system reaches a high local $[\text{Ca}^{2+}]/[\text{PO}_4^{3-}]$ ratio (primarily due to Ca^{2+} release from the pore-walls) that induces a rapid ACP formation: the accompanying depletion of PO_4^{3-} ions thereby retards, or even inhibits, the H(C)A formation.

For both SBF-immersed melt- and sol-gel-derived BGs, Jones *et al.* also highlighted that the $[\text{Ca}^{2+}]/[\text{PO}_4^{3-}]$ ratio of the solution may constitute the primary factor dictating the degree of $\text{ACP} \rightarrow \text{HCA}$ conversion.²³ However, this was attributed to calcite formation superseding that of HCA, stemming from significantly enhanced pH-values observed in their solutions as the BG concentration increased. This explanation is certainly adequate, and is corroborated by other groups,^{19,24} yet, it is doubtful if it applies to our present TRIS-treated samples, as (i) the TRIS solution is (formally) devoid of CO_3^{2-} ions, and PXRD did not reveal any traces of calcium carbonates, while (ii) as opposed to previous studies,^{19,23} the pH-values of our solutions change marginally throughout the *in vitro* tests (see Table 2).

2.6 S58: MBG composition effects

Note that the resulting Ca^{2+} concentration of the medium employed for *in vitro* testing is directly related to both the *amount* of the (M)BG employed and its *composition*. Whereas P-bearing bioactive glasses comprise overall similar stoichiometric P contents (<10 at% out of the cations), their amounts of Ca^{2+} may vary significantly.^{1,2,8,9,28,29} Hence, the larger the Ca content of the M(BG), the higher the $[\text{Ca}^{2+}]/[\text{PO}_4^{3-}]$ ratio of the resulting solution, and the more pronounced *local* ACP precipitation across the material, as we suggested as an explanation for the local Ca and P composition differences observed within the *sbfl6h*₂₀ and *tris16h*₂₀ specimens (Section 2.4). Our proposed dependence of the $\text{ACP} \rightarrow \text{H(C)A}$ crystallization on the $[\text{Ca}^{2+}]/[\text{PO}_4^{3-}]$ ratio of the SBF solution may explain previous results on the rate of HCA formation observed from S85 (of nominal composition $85\text{SiO}_2\text{-}10\text{CaO-}5\text{P}_2\text{O}_5$) relative to Ca-richer MBGs, such as S75 ($75\text{SiO}_2\text{-}20\text{CaO-}5\text{P}_2\text{O}_5$) and S58 ($58\text{SiO}_2\text{-}37\text{CaO-}5\text{P}_2\text{O}_5$):⁹ it was reported that the *ACP formation increases* along the series $\text{S85} < \text{S75} < \text{S58}$, whereas the degree of *HCA crystallization displays the reversed trend*.^{9,10} Identical conclusions were drawn from another study on similar MBG compositions.⁸

Fig. 7 and 8 display the respective solid-state ^{31}P NMR and PXRD results for SBF-soaked S58 specimens that are denoted $\text{S58-}\tau_{20}$, with the immersion period specified either in hours (h) or days (d). Their preparation employed otherwise identical *in vitro* conditions (20 g L^{-1}) as for the S85-deriving *sbfl* τ_{20} series. Now neither experimental technique reveals any trace of crystalline phases. The ^{31}P NMR peak-width narrows marginally (by $\sim 10\%$) over one *week* of SBF-soaking, and remains consistently broader than that observed from the S85 specimen over a markedly




Fig. 7 ^{31}P MAS NMR spectra recorded from pristine S58 (top) and after progressively prolonged SBF-immersion (τ) in hours (h) or days (d), as specified by each sample label $\text{S58-}\tau_{20}$.

shorter time-span of 8 h. Unfortunately, the ion concentrations were not analyzed in these SBF solutions, but we attribute the quenched HCA formation to a high $[\text{Ca}^{2+}]/[\text{PO}_4^{3-}]$ ratio in the solution, which is consistent with the previously reported elevated extent of Ca^{2+} release from this Ca-richer S58 MBG relative to that of S85.^{9,10} This results in an enhanced ACP precipitation occurring inside the S58 pores, compared to those of S85. These explanations are identical to those employed to rationalize the observed differences of the HCA formation in SBF *versus* TRIS solutions (Section 2.5). However, there the effects on the HCA crystallization originated from distinct initial cation concentrations among the *in vitro media*, whereas now, they arise from differences between the *MBG compositions*.

The Ca rich nature of the S58 MBG leads to an overall more depolymerised silicate network in its porewalls compared to the S85 structure.^{12,47} The two MBG structures feature distinct pore arrangements: 2D hexagonal for S58 and 3D bi-continuous cubic




Fig. 8 PXRD patterns recorded for the as-indicated set of SBF-soaked S58 samples.

for S85.¹⁰ Their responses to solutions are different: while the S85 MBG does not reveal any significant alterations in neither of its textural parameters nor small angle PXRD patterns, these change markedly for the S58 MBG even over short exposure intervals (see the ESI†). The S58 surface area decreases, accompanied by an increase of the pore diameter from 9.45 nm to 15.2 nm over seven days in SBF (see the ESI†). The structural modifications are also reflected at a local structural level, where ²⁹Si NMR evidences a progressive network fragmentation on SBF exposure.⁴⁷

Our *in vitro* bioactivity tests on the S85 and S58 MBGs emphasize the difficulties of separating the effects of “internal” from “external” factors when assessing the bioactivity through the rate/amount of H(C)A formed: since the instantaneous Ca and P concentrations of the solution invariably depend on the chemical composition of the biomaterial, it may be difficult to ensure unbiased assessments of (M)BGs exhibiting widely differing compositions, unless very low concentrations are arranged. If the total amount of phosphorus in the surrounding fluid is not significantly larger than that of the bioactivity-probed (M)BG itself, a P-rich specimen may readily appear to exhibit a favourable *in vitro* bioactivity relative to a P-poor counterpart, as the primary source of the produced H(C)A then derives from the biomaterial itself. Conversely, a large stoichiometric $n_{\text{Ca}}/n_{\text{P}}$ ratio of the (M)BG combined with a (too) high concentration may also be detrimental for the observed bioactivity. Hence, the precise (M)BG-loading per solution-volume will be crucial for the apparent “*in vitro* bioactivity”, as discussed previously,^{22,23} and illustrated herein for the S85-deriving trist_{20} and trist_3 samples.

3. Experimental

3.1 MBG sample preparations

The MBG synthesis involved an EISA process⁶ at 40 °C with the P123 triblock copolymer as a structure-directing agent.⁹ Tetraethyl orthosilicate (TEOS), triethyl phosphate (TEP) and $\text{Ca}(\text{NO}_3)_2 \cdot 4\text{H}_2\text{O}$ served as precursors for introducing each of the elements Si, P and Ca, respectively. The reaction product was calcined at 700 °C for 6 h to eliminate organic species and nitrate ions. This procedure was employed to prepare two MBG specimens of nominal molar compositions $10\text{CaO}-85\text{SiO}_2-5\text{P}_2\text{O}_5$ and $37\text{CaO}-58\text{SiO}_2-5\text{P}_2\text{O}_5$, labeled “S85” and “S58”, respectively, according to their mol% of SiO_2 .

The cation compositions of the pristine S85 and S58 samples were determined by XRF spectroscopy, using a Philips PANalytical AXIOS spectrometer (Philips Electronics NV), with X-rays generated by the Rh K_α line at $\lambda = 0.614 \text{ \AA}$. Except for some observed losses of P, the XRF-analyzed compositions of $\text{Ca}_{0.098}\text{Si}_{0.838}\text{P}_{0.064}\text{O}_{1.93}$ (S85) and $\text{Ca}_{0.364}\text{Si}_{0.554}\text{P}_{0.082}\text{O}_{1.68}$ (S58) were close to the nominal ones.

3.2 In vitro studies

An SBF solution was prepared according to Kokubo *et al.*,¹⁵ by dissolving NaCl, KCl, NaHCO_3 , $\text{K}_2\text{HPO}_4 \cdot 3\text{H}_2\text{O}$, $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$, CaCl_2 , and Na_2SO_4 into distilled water. The solution was buffered at pH = 7.45 by using TRIS/HCl. It was passed through 0.22 μm Millipore filters to avoid bacterial contamination.

Additionally, the *in vitro* studies involved a medium of distilled water, buffered by TRIS/HCl to provide the same pH-value as that of the SBF solution.

Our *in vitro* studies used 1.00 g of S85 grains (see Section 3.3) in 50 mL of either SBF or TRIS solutions, equivalent to a mass/volume ratio $m_{\text{S85}}/V = 20 \text{ g L}^{-1}$, whereas those involving TRIS immersion additionally utilized 0.600 g in 200 mL (*i.e.*, $m_{\text{S85}}/V = 3 \text{ g L}^{-1}$). All SBF/TRIS treatments were performed for 8 h or 16 h at 37 °C, employing a sealed polyethylene container under continuous orbital stirring (100 rpm) in an Ecotron HT incubator. Each sample was filtered, washed with water to quench the surface reactions, and subsequently vacuum-dried at 37 °C for several days.

The pH value was determined for each of the four TRIS solutions resulting after S85-immersion, by using an Ilyte system with ion-selective electrodes specific for Na^+ , K^+ and Ca^{2+} . The concentrations of Si, Ca and P were analyzed by inductively coupled plasma/optical emission spectrometry (ICP/OES) in a Perkin Elmer OPTIMA 3300 DV device. Four analyses were performed per solution and element, and their respective average values were calculated.

The bioactivity of S58 was tested for variable SBF-immersion periods between 1 h and 7 days. All tests involved solely SBF and one concentration ($m_{\text{S58}}/V = 20 \text{ g L}^{-1}$), but employed otherwise identical conditions and procedures as described above.

3.3 Scanning electron microscopy

A scanning electron microscope (JSM 74001F; JEOL, Japan) equipped with an energy dispersive X-ray spectrometer (EDS-INCA system, Oxford Instruments) was used to investigate the chemical composition of the S85 MBG before and after SBF/TRIS exposure. Prior to analysis, cross-sections of large grains (>400 μm in diameter) were polished using an SM-09010-CP (JEOL) instrument, operating with an Ar-ion beam.

The size-distribution of the pristine S85 particles (prior to *in vitro* soaking) was estimated by the intercept method,⁴⁸ using a JEOL 6400 scanning electron microscope. Around 1900 particles were considered, and twenty straight lines were drawn on several SEM micrographs recorded at different magnifications. This revealed two maxima at $\sim 20 \mu\text{m}$ and $\sim 300 \mu\text{m}$ of the resulting size-distribution (see Fig. S3 of the ESI†).

3.4 Solid-state NMR

³¹P MAS NMR experiments used an Agilent/Varian/Chemagnetics Infinity-400 spectrometer and a magnetic field of 9.4 T, corresponding to a ³¹P Larmor frequency of $\sim 162.0 \text{ MHz}$. Finely ground powders of the S85- and S58-deriving samples were filled in 6 mm zirconia pencil rotors and spun at 9.0 kHz. Single-pulse (“Bloch-decay”) acquisitions employed $\sim 70^\circ$ flip-angles at a ³¹P nutation frequency of 48 kHz, 600–900 s relaxation delays (selected from separate T_1 saturation-recovery measurements), and the number of accumulated signal transients as follows: ~ 340 (for S85), 128–296 (for S58), and 36 (for HAref). All NMR experimentation was performed without ¹H decoupling; we verified on a selected set of samples that application of high-power decoupling did not affect the ³¹P NMR peak-widths

perceptibly. No signal apodization was used in the data processing. Chemical shifts are reported relative to 85% H₃PO₄.

3.5 Powder X-ray diffraction

PXRD patterns were recorded with Cu K α radiation using a PANalytical X'Pert PRO MPD diffractometer equipped with an X'Celerator detector. A relatively thick layer (~300 μ m) of each powder was dispersed on zero-background Si plates. PXRD patterns were collected using variable slits and 4 cm² irradiated area in the 2 θ range of 10–80° for a total time of 12 h.

4. Conclusions

We explored the ACP and H(C)A growth at the surface of an “S85” MBG of composition Ca_{0.098}Si_{0.838}P_{0.064}O_{1.932} in both SBF and TRIS/HCl-buffered water, and for the latter solution also using two different MBG concentrations of 20 g L⁻¹ and 3 g L⁻¹. We examined the ion release from S85 after SBF- or TRIS-soaking, by determining the concentrations of Si, Ca and P in the surrounding solution, as well as *inside* the leached MBG structure, by using SEM/EDX. Whereas the *tris*16h₂₀ grains displayed a ~60 μ m thick domain of almost pure silica, their *sb*16h₂₀ counterparts verified small but significant amounts of Ca and P throughout all particles of diameter >20 μ m. This is attributed to more extensive local deposits of ACP at the MBG porewalls when they are subjected to SBF, as the latter medium is already supersaturated with respect to apatite.

We demonstrated both PXRD and solid-state ³¹P NMR for estimating the relative amounts of H(C)A and ACP in the biomimetic phosphate layer, and their relative merits were discussed. Generally, the ACP \rightarrow H(C)A crystallization was observed to enhance (i) in the TRIS medium as compared to SBF, as well as (ii) when using more dilute conditions (3 g L⁻¹ of S85). All these findings were rationalized to stem from the relatively high MBG-loading used in our *in vitro* testing, where a fast Ca²⁺ release from the MBG leads to locally high [Ca²⁺]/[PO₄³⁻] ratios of the fluid medium inside the pores. This stimulates phosphate-consuming ACP precipitation (particularly for the calcium- and phosphate-bearing SBF), thereby retarding the HCA crystallization due to insufficient PO₄³⁻ amounts remaining in the fluid medium.²² This feature also explained the herein observed absence of HCA formation from a *bioactive* Ca-rich “S58” MBG (Ca_{0.364}Si_{0.554}P_{0.082}O_{1.68}), as well as rationalizing previous observations^{8–10} that the ACP formation accelerates for increasing amounts of Ca in the MBG, whereas the ACP \rightarrow HCA crystallization diminishes.

Note that our results do *not* imply that TRIS solution is favourable for H(C)A formation *per se*, but merely that the apatite growth increases under more dilute SBF-soaking conditions (*vide infra*), as also reported previously.^{22–25} Problems associated with a retarded/inhibited H(C)A crystallization are expected to reduce in a flowing *in vitro* medium, and hence also under *in vivo* conditions. An optimal *in vitro* testing scenario is achieved when the total amounts of Ca²⁺ and (especially) PO₄³⁻ ions available in the surrounding fluid grossly exceed those present in the biomaterial itself. Such conditions provide a more faithful indicator of the “real” *in vitro* bioactivity, by decoupling

the influences from the MBG composition itself on the HCA growth.

Acknowledgements

This work was supported by the Swedish Research Council (projects VR-NT 2009-7551 and 2010-4943), the Faculty of Sciences at Stockholm University, CICYT Spain (project MAT 2008-00736) and the Comunidad Autónoma de Madrid (projects MAT 2008-0076 and CSO 2010-11384-E). P.N.G. was supported by a postdoctoral grant from the Carl Trygger Foundation. We thank Andy Y. H. Lo for help with recording some of the NMR spectra and Niklas Hedin for providing the hydroxyapatite reference sample.

References

- 1 L. L. Hench, *J. Am. Ceram. Soc.*, 1991, **74**, 1487–1510.
- 2 M. Vallet-Regí, C. V. Ragel and A. J. Salinas, *Eur. J. Inorg. Chem.*, 2003, 1029–1042.
- 3 D. Arcos and M. Vallet-Regí, *Acta Biomater.*, 2010, **6**, 2874–2888.
- 4 L. L. Hench and J. M. Polak, *Science*, 2002, **295**, 1014–1017.
- 5 M. N. Rahaman, D. E. Day, B. Sonny Bal, Q. Fu, S. B. Jung, L. F. Bonewald and A. P. Tomsia, *Acta Biomater.*, 2011, **7**, 2355–2373.
- 6 C. J. Brinker, Y. F. Lu, A. Sellinger and H. Y. Fan, *Adv. Mater.*, 1999, **11**, 579–585.
- 7 X. X. Yan, C. Z. Yu, X. F. Zhou, J. W. Tang and D. Y. Zhao, *Angew. Chem., Int. Ed.*, 2004, **43**, 5980–5984.
- 8 X. X. Yan, X. H. Huang, C. Z. Yu, H. X. Deng, Y. Wang, Z. D. Zhang, S. Z. Qiao, G. Q. Lu and D. Y. Zhao, *Biomaterials*, 2006, **27**, 3396–3403.
- 9 A. López-Noriega, D. Arcos, I. Izquierdo-Barba, Y. Sakamoto, O. Terasaki and M. Vallet-Regí, *Chem. Mater.*, 2006, **18**, 3137–3144.
- 10 I. Izquierdo-Barba, D. Arcos, Y. Sakamoto, O. Terasaki, A. López-Noriega and M. Vallet-Regí, *Chem. Mater.*, 2008, **20**, 3191–3198.
- 11 X. Li, X. P. Wang, H. R. Chen, P. Jiang, X. P. Dong and J. L. Shi, *Chem. Mater.*, 2007, **19**, 4322–4326.
- 12 E. Leonova, I. Izquierdo-Barba, D. Arcos, A. López-Noriega, N. Hedin, M. Vallet-Regí and M. Edén, *J. Phys. Chem. C*, 2008, **112**, 5552–5562.
- 13 P. N. Gunawidjaja, A. Y. H. Lo, I. Izquierdo-Barba, A. García, D. Arcos, B. Stevansson, J. Grins, M. Vallet-Regí and M. Edén, *J. Phys. Chem. C*, 2010, **114**, 19345–19356.
- 14 A. García, M. Cicuéndez, I. Izquierdo-Barba, D. Arcos and M. Vallet-Regí, *Chem. Mater.*, 2009, **21**, 5474–5484.
- 15 T. Kokubo, H. Kushitani, S. Sakka, T. Kitsugi and T. Yamamuro, *J. Biomed. Mater. Res.*, 1990, **24**, 721–734.
- 16 T. Kokubo and H. Takadama, *Biomaterials*, 2006, **27**, 2907–2915.
- 17 M. Bohner and J. Lemaitre, *Biomaterials*, 2009, **30**, 2175–2179.
- 18 H. B. Pan, X. L. Zhao, B. W. Darvell and W. W. Lu, *Acta Biomater.*, 2010, **6**, 4181–4188.
- 19 M. Cerruti, D. Greenspan and K. Powers, *Biomaterials*, 2005, **26**, 1665–1674.
- 20 I. Izquierdo-Barba, A. J. Salinas and M. Vallet-Regí, *J. Biomed. Mater. Res.*, 2000, **51**, 191–199.
- 21 D. Zhang, M. Hupa, H. T. Aro and L. Hupa, *Mater. Chem. Phys.*, 2008, **111**, 497–502.
- 22 H. W. Yan, K. Zhang, C. F. Blanford, L. F. Francis and A. Stein, *Chem. Mater.*, 2001, **13**, 1374–1382.
- 23 J. R. Jones, P. Sepulveda and L. L. Hench, *J. Biomed. Mater. Res.*, 2001, **58**, 720–726.
- 24 P. Sepulveda, J. R. Jones and L. L. Hench, *J. Biomed. Mater. Res., Part A*, 2002, **61**, 301–311.
- 25 K. Zhang, H. W. Yan, D. C. Bell, A. Stein and L. F. Francis, *J. Biomed. Mater. Res., Part A*, 2003, **66**, 860–869.
- 26 R. D. Rawlings, *J. Mater. Sci. Lett.*, 1992, **11**, 1340–1343.
- 27 Z. Strnad, *Biomaterials*, 1992, **13**, 317–321.
- 28 R. Hill, *J. Mater. Sci. Lett.*, 1996, **15**, 1122–1125.
- 29 I. Lebecq, F. Désanglois, A. Leriche and C. Follet-Houttemane, *J. Biomed. Mater. Res., Part A*, 2007, **83**, 156–168.

- 30 M. D. O'Donnell, S. J. Watts, R. G. Hill and R. V. Law, *J. Mater. Sci.: Mater. Med.*, 2009, **20**, 1611–1618.
- 31 M. Edén, *J. Non-Cryst. Solids*, 2011, **357**, 1595–1602.
- 32 R. G. Hill and D. S. Brauer, *J. Non-Cryst. Solids*, 2011, **357**, 3884–3887.
- 33 S. Hayakawa, K. Tsuru, C. Ohtsuki and A. Osaka, *J. Am. Ceram. Soc.*, 1999, **82**, 2155–2160.
- 34 K. S. K. Lin, Y. H. Tseng, Y. Mou, Y. C. Hsu, C. M. Yang and J. C. C. Chan, *Chem. Mater.*, 2005, **17**, 4493–4501.
- 35 L. J. Skipper, F. E. Sowrey, R. Rashid, R. J. Newport, Z. Lin and M. E. Smith, *Phys. Chem. Glasses*, 2005, **46**, 372–376.
- 36 E. Dietrich, H. Oudadesse, M. Le Floch, B. Bureau and T. Gloriant, *Adv. Eng. Mater.*, 2009, **11**, B98–B105.
- 37 C. Ohtsuki, T. Kokubo and T. Yamamuro, *J. Non-Cryst. Solids*, 1992, **143**, 84–92.
- 38 M. Bini, S. Grandi, D. Capsoni, P. Mustarelli, E. Saino and L. Visai, *J. Phys. Chem. C*, 2009, **113**, 8821–8828.
- 39 V. FitzGerald, K. O. Drake, J. R. Jones, M. E. Smith, V. Honkimaki, T. Buslaps, M. Kretschmer and R. J. Newport, *J. Synchrotron Radiat.*, 2007, **14**, 492–499.
- 40 K. J. D. MacKenzie and M. E. Smith, *Multinuclear Solid-State NMR of Inorganic Materials*, Pergamon Press, Amsterdam, 2002.
- 41 R. Mathew, P. N. Gunawidjaja, I. Izquierdo-Barba, K. Jansson, A. García, D. Arcos, M. Vallet-Regí and M. Edén, *J. Phys. Chem. C*, 2011, **115**, 20572–20582.
- 42 J. Rodríguez-Carvajal and T. Roisnel, “FULLPROF.98 and WINPLOTR New Windows 95/NT Applications for Diffraction,” *Commission on Powder Diffraction, International Union of Crystallography*, 1998, No. 20, pp. 35–36.
- 43 V. K. Pecharsky and P. Y. Zavalij, *Fundamentals of Powder Diffraction and Structural Characterization of Materials*, Springer, 2009.
- 44 M. Ogino and L. L. Hench, *J. Non-Cryst. Solids*, 1980, **38/39**, 673–678.
- 45 Ö. H. Andersson and K. H. Karlsson, *J. Non-Cryst. Solids*, 1991, **129**, 145–151.
- 46 V. Banchet, E. Jallot, J. Michel, L. Wortham, D. Laurent-Maquin and G. Balossier, *Surf. Interface Anal.*, 2004, **36**, 658–665.
- 47 P. N. Gunawidjaja, R. Mathew, I. Izquierdo-Barba, A. Y. H. Lo, A. García, D. Arcos, M. Vallet-Regí and M. Edén, *Philos. Trans. R. Soc., A*, 2012, **370**, 1376–1399.
- 48 ASTM E 384-84, *Standard Test Method for Microhardness of Materials*, Philadelphia, USA, ASTM Committee on Standards, 1984, pp. 384–89.